Trospium Chloride Tablet, Film Coated
Product Images NDC 72789-348

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 72789-348). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789348 Label (72789348)

Label for Trospium Chloride 20 mg film-coated tablets, containing 60 tablets per container. The label displays the NDC 72789-348-60 and specifies that the product is Rx only. Marketed and packaged by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK, and manufactured by Perrigo in Minneapolis, MN. The label includes storage instructions and a barcode.*

FDA Label Image

Chemical Structure (Image 01)

Chemical structure diagram of trospium chloride showing its molecular components and bonds, including a quaternary ammonium ion with chloride counterion and bicyclic and diphenyl moieties.*

FDA Label Image

Figure 1 (Image 02)

A line graph showing plasma concentration (ng/mL) over time (hours post-dose). The graph displays initial peak plasma concentration within a few hours after dosing, followed by a gradual decline to near zero concentration by 48 hours post-dose. Error bars indicate variability at each time point.*

FDA Label Image

Figure 2 (Image 03)

A line graph comparing mean change values over weeks of treatment between placebo and Trospium Chloride tablets groups. The x-axis represents weeks of treatment (1, 4, 12), and the y-axis shows mean change with standard error (SE). Data points with error bars indicate statistical significance values at various weeks.*

FDA Label Image

Figure 3 (Image 04)

A line graph comparing mean change over weeks of treatment between two groups: Placebo (N=256) and Trospium Chloride Tablets (N=253). The x-axis represents weeks of treatment (1, 4, 12), and the y-axis shows mean change with standard error bars. Statistical p-values are marked for differences at weeks 1, 4, and 12.*

FDA Label Image

Figure 4 (Image 05)

A line graph comparing the mean ± standard error change over weeks of treatment between placebo and Trospium Chloride tablets (20 mg). The x-axis represents weeks of treatment (1, 4, and 12), and the y-axis shows mean change values, with Trospium Chloride showing a greater reduction compared to placebo. Statistical significance values are noted for each time point.*

FDA Label Image

Figure 5 (Image 06)

A line graph depicting mean change over time in a clinical measure during treatment weeks 1, 4, and 12. Two groups are compared: placebo (N=325, shown with a dashed line and open circles) and trospium chloride tablets (N=323, solid line with filled circles). Trospium chloride consistently shows a greater negative mean change compared to placebo, with statistically significant differences at each time point (p<0.001).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.